news
Over 250 drug list prices increased in 2020, says new report
Drug makers have hiked the price of over 250 drugs in the US so far in 2020, according to new reports.
List view / Grid view
Industry Insight
article
Intellectual property, divestments, fragmentation and the future: M&A in life sciences
Mergers and acquisitions in any market can define the landscape for its players. In this article, Emma Danks of Taylor Wessing reflects on recent M&A activity in the biopharmaceutical industry, highlighting influencing trends and what this might mean for the future.
news
New steps taken to lower US prescription drug prices
The FDA has announced that a notice of proposed rulemaking has been issued that would allow for the importation of certain prescription drugs from Canada which could lead to lower prescription drug prices.
article
EPR’s news round-up 2019: the stories that defined the year
This article highlights the 10 most popular news stories published by European Pharmaceutical Review in 2019.
news
Dr Stephen Hahn appointed as new FDA commissioner
Dr Stephen Hahn has been voted into the role of FDA commissioner by the US Senate, taking over the role from Ned Sharpless.
article
The real reason you’re struggling to stay compliant
For companies in highly regulated industries, compliance is second only to survival as a business. Yet why do so many companies struggle with compliance? Dr Rebecca Godfrey explores this issue and provides practical steps that companies can take to ensure best practice.
news
Survey finds smaller enterprises will drive life sciences in Scotland
Researchers have revealed that small- and medium-sized companies will by key in the growth of the life sciences sector in Scotland.
news
Report links greater generic competition and lower generic drug prices
A new report from the FDA has shown that greater competition among generic drug makers is associated with lower generic drug prices.
news
FDA grants accelerated approval for treatment of rare DMD mutation
The FDA has granted accelerated approval to Vyondys 53 for the treatment of patients with Duchenne muscular dystrophy containing a mutation of the dystrophin gene that is amenable to exon 53 skipping.
article
The global cannabinoid pharmaceutical industry
Cannabinoids are of growing interest in the pharmaceutical industry. Mark Tucker explains how this class of compounds is viewed across the world and why regulations surrounding them hinder their progress, yet remain necessary.
news
Sanofi announces it will acquire Synthorx for $2.5 billion
Sanofi has announced it is to acquire Synthorx to bolster its immuno-oncology pipeline for $2.5 billion.
news
Pharma industry should stimulate bolder communications, says report
A new report has been published which draws on expertise from within and beyond the pharmaceutical industry to make recommendations for pharma communicators.
news
FDA issues warning letter for misrepresentation of drug in advertisement
Alkermes, Inc. have received the warning letter after a promotional material review found it failed to adequately represent the risks of using the drug Vivitrol for patients with opioid use disorder.
news
USMCA to stabilise biologic drug prices in North America
The newly signed deal between the US, Mexico and Canada will hold down the price of biologic drugs in the continent, according to a report.
article
Optimising artificial intelligence in the pharmaceutical industry
Artificial intelligence can be applied to almost every part of the pharma industry. Christopher Rafter discusses its many uses and how the adoption of machine learning will increase in the future.
